Australian biotech Microba brings gut analysis to Europe with pathology leader SYNLAB

The partnership will bring together the cutting-edge metagenomics sequencing and bioinformatics of Microba with the expertise of SYNLAB’s laboratory services team to deliver new gastrointestinal analysis services to their network of practising doctors and clinics.

Microba was developed out of field-leading research from the University of Queensland, launching Australia’s first detailed gut microbiome analysis in June 2018. 

The biotech has now assisted more than 10,000 Australians to assess their gut health individually or with an Australian healthcare professional.

SYNLAB is the market leader in medical diagnostic services in Europe, with a presence in more than 40 countries across four continents.

The co-delivered MyBiome gut microbiome analysis will be launched initially in two selected countries to provide healthcare professionals with access to new and actionable information on their patients’ health.

Blake Wills, CEO of Microba, emphasised that the launch would expand the availability of the company’s world-leading gut microbiome analysis technology to customers in Europe, and assist Microba in their  global pursuit of driving new discoveries and improving human health.

“Microba’s partnership with SYNLAB is a great example of two international forces joining together to embrace next-generation technologies and support local healthcare,” said Wills.

“It will allow us to expand the reach of our technology into the European market, and bring innovation born in Australia into larger overseas markets to positively impact more lives,” he added.

Microba’s award-winning proprietary Metagenomic Analysis Platform (MAP™) will be utilised to deliver the MyBiome analysis.

Mr Wills said that delivering an analysis into the European market in partnership with SYNLAB allowed Microba to access large, established markets with unmet demand for comprehensive microbiome analysis services.

“SYNLAB is a global leader in delivering medical diagnostic services and we are proud to be partnering to add advanced gut microbiome analysis to their portfolio, powered by Microba’s technology,” he said.

Chief Medical Officer of SYNLAB Group, Dr Santiago Valor said, “We are excited to start this collaboration with Microba. SYNLAB’s commitment to medical excellence in diagnostics is underlined by complementing our test portfolio with the MyBiome analysis.”

“Together we set a sign for continuous medical advancement to the benefit of patients and customers.”

In addition to powering the new analysis service in Europe with SYNLAB, and a continuing partnership in the United States, Microba also works with research groups and healthcare organisations to advance global understanding of the human gut microbiome and its influence on health.

ENDS